



ASX Announcement

05 September 2025

Cambium Bio Signs Strategic MoU with Benta SAS to Commercialise Elate Ocular® in Europe and Middle East

Second platelet-lysate licensing deal in 3 days demonstrates strong commercial interest in platform technology

Sydney, Australia; 05 September 2025: Cambium Bio Limited (ASX:CMB) ("Cambium Bio", "Cambium" or "Company"), a clinical-stage regenerative medicine company, is pleased to announce it has entered into a Memorandum of Understanding ("MoU") with Benta SAS ("Benta"), a leading French pharmaceutical company, to establish a strategic partnership for the development and commercialisation of Elate Ocular® (CAM-101) for dry eye disease in Europe and the Middle East.

Key Transaction Highlights

Strategic Partner Profile

- **Benta SAS** is a premier pharmaceutical company headquartered in France, part of the Benta Group, with an established presence across 40 countries
- Strong manufacturing and distribution capabilities with multiple GMP-certified facilities across Europe and the Middle East
- Proven expertise in blood-derived therapeutics through existing partnership with CSL Behring for manufacturing and distribution in the Middle East
- Established ophthalmology franchise with various OTC products for dry eye treatment

Partnership Structure

- **Territory:** Exclusive rights for Europe and the Middle East
- **Product:** Elate Ocular® (CAM-101), a regenerative medicine based on Fibrinogen-Depleted Human Platelet Lysate for dry eye disease
- **Business Models:** Parties to establish either:
 - Direct Licensing Agreement
 - A new corporate entity ("NewCo") to hold and manage rights

- For personal use only
- Joint Venture arrangement
 - **Technology Transfer:** Cambium to provide exclusive license rights, intellectual property, manufacturing know-how, documentation, and data packages for regulatory approvals and commercialisation

Strategic Rationale

- **Platform Validation:** Second licensing agreement for platelet-lysate technology within 3 days, following the US\$2.0M+ Keke MedTech deal announced on 2 September 2025
- **Geographic Expansion:** Access to major European and Middle Eastern markets for dry eye patients
- **Manufacturing Synergies:** Leverages Benta's established expertise in blood-derived product manufacturing
- **Regulatory Support:** Benta to facilitate exchanges with French and EMEA regulatory authorities

Next Steps

- Execution of definitive agreements within four months
- Establishment of corporate structure or contractual arrangements
- Initiation of regulatory submissions in France and targeted jurisdictions
- Technology transfer and manufacturing setup

Management Commentary

Karolis Rosickas, Chief Executive Officer of Cambium Bio, commented:

"We are very excited about this partnership with Benta and the opportunity to leverage their extensive experience in blood-derived therapeutics, ophthalmology, and their established manufacturing and distribution platform to serve dry eye patients in Europe and the Middle East. This marks our second deal for our platelet-lysate technology platform and demonstrates the scalability of our technology across multiple therapeutic areas and geographies.

The rapid succession of these strategic partnerships validates both the clinical potential of our human platelet lysate platform and the significant commercial interest from established pharmaceutical companies. With Benta's proven track record in manufacturing CSL's blood-derived products and their strong presence in ophthalmology markets, we have found an ideal partner to advance Elate Ocular® in these important territories."

Bernard Tannoury, Chairman & CEO of Benta Group, commented:

"Following comprehensive evaluation of Cambium Bio's technology and clinical data, we are convinced that Elate Ocular® represents a breakthrough approach to treating dry eye disease. The product's differentiated mechanism of action and compelling safety and efficacy profile position it to become a cornerstone therapy in ophthalmology.

Our decision to partner with Cambium Bio reflects both the strength of their science and the strategic fit with our capabilities. Through our long-standing partnership with CSL Behring, we've developed world-class expertise in manufacturing and commercialising blood-derived therapeutics. Combined with our established ophthalmology presence across Europe and the Middle East – where we already serve thousands of dry eye patients – we are uniquely positioned to maximise the potential of Elate Ocular®.

This partnership exemplifies Benta's commitment to bringing innovative biologics to patients who need them most. We look forward to working with the Cambium Bio team to transform the treatment landscape for dry eye disease across our territories."

About Benta SAS

Benta SAS is a leading pharmaceutical company headquartered in France and part of the Benta Group. With operations spanning 40 countries, Benta specialises in the manufacturing and distribution of high-quality pharmaceutical products and medical devices across various therapeutic areas, including cardiovascular, central nervous system, diabetes, dermatology, urology, transplant, anaesthesia, and ophthalmology. The company holds European Good Manufacturing Practice (GMP) certification and has established partnerships with major pharmaceutical companies, including CSL Behring, for which it manufactures and distributes blood-derived products in the Middle East region.

- ENDS -

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Cambium Bio Limited.

For further information, please contact:
Acclime Australia – Company Secretary
Email: info@cambium.bio

Cambium Bio Limited
Unit 2.06/31 Lexington Drive, Bella Vista, NSW 2153 Australia
ABN 13 127 035 358
Phone: 1300 995 098
www.cambium.bio